TG Therapeutics TGTX
United StatesHealthcare · BiotechnologyUSD
69.71 USD (+31.7%)
7 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
TG Therapeutics is a commercial-stage biopharmaceutical company that develops and sells therapies for the treatment of autoimmune and oncological diseases, with its lead product targeting multiple sclerosis.
Key points
from its scores- ✓Good share-price trend8.9
- ✕Little or no dividend1.5
- ✕Unfavourable risk and backdrop2.1
- ✕Demanding valuation3.7
AI analysis
bottom line, main risk, context and newsStrong commercial momentum and a solid balance sheet (liquidity 4.27) do not offset the lack of profitability and demanding valuation until a path to sustained earnings is confirmed.
TG Therapeutics shows exceptional revenue growth of 70.30% and a gross margin of 82.37%, but net profitability is still negative (earnings growth of -70.60%) and the valuation is demanding (EV/EBITDA of 56.53), leaving upside highly dependent on the commercial execution of its lead drug.
Dependence on the commercial success of a single lead drug: any regulatory, competitive, or market adoption setback could jeopardize the viability of the business.
Context and risks
US biopharmaceutical company with no material exposure to interest rates, commodities, or shipping routes. The adjustment reflects the inherent regulatory risk of the biotechnology sector: dependence on FDA approvals and the commercial evolution of its lead drug, whose success will determine the viability of the business.
Is TG Therapeutics stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 131% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 19.3 | 26.7 | −28% |
| EV / EBITDA | 56.5 | 14.5 | +291% |
| Price / book | 12.9 | 4.1 | +213% |
| Price / sales | 10.1 | 3.4 | +197% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 3.7 out of 10 (median for Healthcare: 4.7).
Average analyst target: 69.71 USD, +31.7% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 6.4 (sector 5.5), Growth 5.0 (sector 6.6).
Classic formulas with standard assumptions (0.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 19.3
- Forward P/E
- 19.6
- EV / EBITDA
- 56.5
- Price / book
- 12.9
- Price / sales
- 10.1
- PEG
- 1.61
- Market cap
- 8.1B USD
- Enterprise value
- 7.7B USD
Profitability
- ROE
- 100.3%
- ROA
- 7.3%
- ROIC (approx.)
- 5.2%
- Gross margin
- 82.4%
- Operating margin
- 9.0%
- Net margin
- 55.2%
- Free cash flow
- 59.1M USD
- FCF yield
- 0.7%
- Cash conversion
- 43%
Solvency
- Total debt
- 754.4M USD
- Net debt
- 202.2M USD
- Cash
- 552.2M USD
- EBITDA
- 136.5M USD
- Net debt / EBITDA
- 1.48
- Debt / equity
- 124.89
- Current ratio
- 4.27
- Quick ratio
- 3.55
Growth
- Revenue growth
- +70.3%
- Earnings growth
- −70.6%
- EPS (TTM)
- 2.75 USD
- EPS (forward)
- 2.71 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 1.80
- Analyst consensus
- Strong buy (7)
- Target price
- 69.71 USD
- 52-week range
- 26.76 – 59.30
Recent news
All TGTX news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about TG Therapeutics
Is TG Therapeutics stock cheap or expensive?
On P/E and EV / EBITDA, it trades 131% above the Healthcare median on average. Valuation score: 3.7 out of 10 (median for Healthcare: 4.7). Average analyst target: 69.71 USD, +31.7% versus the price. This is not investment advice.
What score does TG Therapeutics get on MeridIAn Screener?
It scores 4.9 out of 10, rank 1,768 of 2,130 (better than 17% of the companies analysed). Its strongest category is Momentum (8.9) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is TG Therapeutics's P/E ratio?
Its P/E is 19.3: the share price equals 19.3 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 19.6.
How much is TG Therapeutics worth on the stock market?
Its market capitalisation is 8.1B USD and its enterprise value, debt included, is 7.7B USD.
How much debt does TG Therapeutics have?
Its net debt (debt minus cash) is 202.2M USD. That is 1.48 times its EBITDA; the Healthcare median is 1.53.
Does TG Therapeutics pay a dividend?
It pays no dividend, or almost none.
How has TG Therapeutics stock performed over the last year?
It has risen 56.8% over the last year, excluding dividends. Over the last 52 weeks it has traded between 26.76 and 59.30 USD. Past performance does not guarantee future results.
What do analysts think of TG Therapeutics?
7 analysts cover it; their average recommendation is “Strong buy” and their average target is 69.71 USD (+31.7% versus the price). It is an estimate, not market data.